December 17, 2018

Alexandria, Va. – The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) today published a joint analysis comparing the results of both organizations’ value frameworks in ASCO’s Journal of Clinical Oncology (JCO). The analysis found that the frameworks produce comparable measures of the clinical benefits of new therapies in approximately two-thirds of the more than 100 treatment comparisons that were examined. It also identified a number of factors that may contribute to discordant scores, revealing potential ways for both organizations to refine their frameworks in the future.

October 5, 2018

Statement from American Society of Clinical Oncology (ASCO) President Monica M. Bertagnolli, MD, FACS, FASCO, on the Journal of the American Medical Association Study, "Factors Associated with Cancer Disparities Among Low-, Medium-, and High-Income U.S. Counties"

September 27, 2018

ASCO applauds Congress for passing a $2 billion increase in funding for the National Institutes of Health (NIH), which will bring NIH's budget to a total of $39.1 billion and the National Cancer Institute's to a total of $6.147 billion.

September 25, 2018

The American Society of Clinical Oncology presented Representative Kevin Yoder (KS-03) with the 2018 Congressional Leadership Award today. Each year, ASCO presents this Award to a Member of Congress who has continuously supported legislation that promotes an improved practice environment for the oncology community and improves the quality of care for cancer patients.

September 13, 2018

The American Society of Clinical Oncology (ASCO) today issued a set of recommendations for overcoming financial barriers to patient participation in cancer clinical trials.

August 31, 2018

Senator John McCain will lie in state in the U.S. Capitol Building today. The following ASCO statement pays tribute to his life-long service to our country.

August 30, 2018

Alexandria, Va. —In a new position statement, the American Society of Clinical Oncology (ASCO) warns that some of the practices of pharmacy benefit manager (PBM) companies use could hinder patient access to timely, high-quality cancer care. ASCO describes a range of PBM practices that, while they may be intended to help control costs in cancer care, might compromise physicians’ ability to provide the right treatment at the right time for people with cancer. 

August 8, 2018

ASCO strongly opposes the Centers for Medicare & Medicaid Services (CMS) decision to allow Medicare Advantage plans to employ step therapy across physician-administered and self-administered drugs under Medicare Part B and Part D.

June 2, 2018

As nearly 40,000 oncology professionals from around the world gather in Chicago for the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO) to learn about the latest in clinical cancer research -- from new treatment options and advances in precision medicine to insight for improving access to care -- ASCO welcomes the U.S. Food and Drug Administration's (FDA) announcement that it is advancing new policies to make the drug review and approval process more modern, more scientifically rigorous, and more efficient.

April 24, 2018

Alexandria, Va. – An analysis published today in the American Society of Clinical Oncology’s (ASCO) Journal of Oncology Practice (JOP), suggests that including cancer drug costs in bundled payments under Medicare risks destabilizing the cancer care delivery environment. According to the report, Medicare reimbursement would vary widely in such a model depending on the mix of patient conditions practices treat, rather than the quality of care they provide—with reimbursement to practices that see a large volume of complex patients declining significantly from current levels.

February 20, 2018

ASCO Statement on JAMA Internal Medicine’s Cigarette, Cigar, and Pipe Use Mortality Risk Study

Statement from Bruce E. Johnson, MD, FASCO, President of the American Society of Clinical Oncology (ASCO)

February 7, 2018

The American Society of Clinical Oncology (ASCO) today released its review of leading oncology pathway vendors in the United States. "Oncology Clinical Pathways: Charting the Landscape of Pathway Providers," published in the Journal of Oncology Practice (JOP), examines the clinical pathways offered by six commercial vendors using the society's criteria for high-quality clinical pathways.

January 30, 2018

"Over the past few decades we’ve seen global cancer death rates drop thanks to dramatic improvements in diagnosis and treatment. But the unfortunate reality is that millions of patients worldwide are not yet reaping the benefits of the progress we’ve made because of inability to access care. All too often, where someone lives dictates their chances of surviving cancer."

December 1, 2017

We are deeply concerned about the sequestration cuts that would be triggered by passage of the Tax Cuts and Jobs Act. The core mission of the American Society of Clinical Oncology (ASCO) is to ensure that cancer patients have meaningful access to high-quality cancer care. We fear that the current proposal will harm patients with cancer by reducing access to care, a situation that could adversely impact treatment needed to extend and save patients' lives.

September 8, 2017

ALEXANDRIA, Va. – The American Society of Clinical Oncology, Inc. (ASCO®) has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program™, LLC (QCP). The accreditations were given today at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.

Pages